Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS

Infection

Volumn 39, Issue 1, 2011, Pages 3-12

  Plettenberg, A ^a   Brockmeyer, N H ^b,c   Haastert, B ^d   Michalik, C ^e   Dupke, S ^f   Schewe, K ^g   Rausch, M ^h   Hower, M ⁱ   Ulmer, A ^j   Wolf, E ^k   Lorenzen, T ^a   Arendt, G ^l   Jansen, K ^b  

^a Ifi Institute   (Germany)

^b Competence Network for HIV/AIDS ^*  (Germany)

^c ST JOSEF HOSPITAL   (Germany)

^d MediStatistica ^*  (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f Clinical Centre   (Germany)

^g Infektionsmedizinisches Centrum Hamburg   (Germany)

^h Clinical Centre Fuggerstrae   (Germany)

ⁱ City Clinic   (Germany)

^j Clinical Centre Ulmer/Frietsch/Mueller   (Germany)

^k Diagnostik München   (Germany)

^l University Clinic   (Germany)

more..

Author keywords

CD4 cell count; Clinical course of HIV; Cohort study; HAART initiation; HIV AIDS

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DEMOGRAPHY; DISEASE COURSE; FEMALE; FOLLOW UP; GERMANY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PROBABILITY;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; GERMANY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952447354     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-010-0070-8     Document Type: Article

References (36)

1. S Emery JA Neuhaus AN Phillips, et al. 2008 Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study J Infect Dis 197 1133 1144 18476292 10.1086/586713 (Pubitemid 351590049)
2. Strategies for Management of Antiretroviral Therapy (SMART) Study Group 2006 CD4+ count-guided interruption of antiretroviral treatment N Engl J Med 355 2283 2296 10.1056/NEJMoa062360 (Pubitemid 44837777)
3. MM Kitahata SJ Gange AG Abraham, et al. 2009 Effect of early versus deferred antiretroviral therapy for HIV on survival N Engl J Med 360 18 1815 1826 19339714 10.1056/NEJMoa0807252 1:CAS:528:DC%2BD1MXlsVGmtrY%3D
4. JA Sterne M May D Costagliola, et al. 2009 Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies Lancet 373 9672 1352 1363 19361855 10.1016/S0140-6736(09)60612-7
5. L Ahdieh-Grant TE Yamashita JP Phair, et al. 2003 When to initiate highly active antiretroviral therapy: a cohort approach Am J Epidemiol 157 738 746 12697578 10.1093/aje/kwg036 (Pubitemid 36423087)
6. K Anastos Y Barrón P Miotti, et al. 2002 Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease Arch Intern Med 162 1973 1980 12230420 10.1001/archinte.162.17.1973
7. MD Hughes HR Ribaudo 2008 The search for data on when to start treatment for HIV infection J Infect Dis 197 1084 1086 18462158 10.1086/586712 (Pubitemid 351590042)
8. M Opravil B Ledergerber H Furrer, et al. 2002 Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count >350 × 10(6)/l AIDS 16 1371 1381 12131214 10.1097/00002030- 200207050-00009 1:CAS:528:DC%2BD38XlvVSgtbo%3D (Pubitemid 34722069)
9. FJ Palella Jr M Deloria-Knoll JS Chmiel, et al. 2003 Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata Ann Intern Med 138 620 626 12693883
10. TR Sterling RE Chaisson RD Moore 2001 HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy AIDS 15 2251 2257 11698698 10.1097/00002030-200111230-00006 1:CAS:528:DC%2BD38XnsVyjsg%3D%3D (Pubitemid 34059832)
11. 3: disease progression, treatment durability, and drug toxicity Clin Infect Dis 36 812 815 12627368 10.1086/367934 (Pubitemid 36337989)
12. A Zolopa J Andersen W Powderly, et al. 2009 Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial PLoS ONE 4 5 e5575 19440326 10.1371/journal.pone.0005575
13. P Grant A Zolopa 2009 Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose Curr HIV/AIDS Rep 6 2 63 67 19358776 10.1007/s11904-009-0010-3
14. AN Phillips B Gazzard R Gilson, et al. 2007 Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count AIDS 21 13 1717 1721 17690569 10.1097/QAD.0b013e32827038bf (Pubitemid 47237558)
15. MT May JA Sterne D Costagliola, et al. 2006 HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis Lancet 368 9534 451 458 16890831 10.1016/S0140-6736(06)69152-6 (Pubitemid 44142767)
16. F Bonnet R Thiébaut G Chêne, et al. 2005 Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002 HIV Med 6 3 198 205 15876287 10.1111/j.1468-1293.2005.00290.x 1:STN:280: DC%2BD2M3jvFejsA%3D%3D (Pubitemid 40740337)
17. G Chêne JA Sterne M May, et al. 2003 Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies Lancet 362 9385 679 686 12957089 10.1016/S0140-6736(03)14229-8 (Pubitemid 37101064)
18. LP Jacobson R Li J Phair, et al. 2002 Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression Am J Epidemiol 155 8 760 770 11943695 10.1093/aje/155.8.760 1:STN:280:DC%2BD383hsF2lsg%3D%3D (Pubitemid 34297657)
19. MA Thompson JA Aberg P Cahn, et al. 2010 Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA Panel JAMA 304 3 321 333 20639566 10.1001/jama.2010.1004 1:CAS:528: DC%2BC3cXpt1Sgs78%3D
20. Clumeck N, Dedes N, Pozniak A, et al. Clinical management and treatment of HIV infected adults in Europe. EACS Guidelines Version 5.2. Available online at: http://www.europeanaidsclinicalsociety.org/guidelines.asp. Accessed 16 September 2010.
21. B Lau SJ Gange GD Kirk, et al. 2009 Evaluation of human immunodeficiency virus biomarkers: inferences from interval and clinical cohort studies Epidemiology 20 5 664 672 19478669 10.1097/EDE.0b013e3181a71519
22. A Jaén A Esteve JM Miró, et al. 2008 Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain) J Acquir Immune Defic Syndr 47 2 212 220 18297762 10.1097/QAI.0b013e31815ee282 (Pubitemid 351172189)
23. W Stöhr D Dunn K Porter, et al. 2007 CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003 HIV Med 8 3 135 141 17461856 10.1111/j.1468-1293.2007.00443.x (Pubitemid 46915683)
24. M May JA Sterne C Sabin, et al. 2007 Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies AIDS 21 9 1185 1197 17502729 10.1097/QAD.0b013e328133f285 (Pubitemid 46763289)
25. C Ho S Lee Kh Wong, et al. 2007 Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients HIV Med 8 3 181 185 17461862 10.1111/j.1468-1293.2007.00450.x (Pubitemid 46915689)
26. 3 Antivir Ther 12 6 941 947 17926648 1:CAS:528:DC%2BD2sXht1Ggu77E (Pubitemid 47492563)
27. M Locadia RA van Grieken JM Prins, et al. 2006 Patients' preferences regarding the timing of highly active antiretroviral therapy initiation for chronic asymptomatic HIV-1 infection Antivir Ther 11 3 335 341 16759050 (Pubitemid 43823552)
28. L Fardet M Mary-Krause I Heard, et al. 2006 Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response HIV Med 7 8 520 529 17105511 10.1111/j.1468-1293.2006. 00414.x 1:STN:280:DC%2BD28nmvFSkug%3D%3D (Pubitemid 44742352)
29. B Ledergerber JD Lundgren AS Walker, et al. 2004 Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes Lancet 364 9428 51 62 15234856 10.1016/S0140-6736(04)16589-6 (Pubitemid 38968625)
30. K Jansen C Michalik M Hahn Competence Network for HIV/AIDS, et al. 2009 The Patient Cohort of the German Competence Network For HIV/AIDS (KompNet): a profile Eur J Med Res 14 10 323 331 19666392 1:STN:280:DC%2BD1MrksFCqsQ%3D%3D
31. K Jansen NH Brockmeyer M Hahn Competence Network for HIV/AIDS, et al. 2009 Epidemiological composition, clinical and treatment characteristics of the patient cohort of the German Competence Network for HIV/AIDS Eur J Med Res 14 10 415 425 19748848
32. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley; 1980. p. 21-38.
33. JE Kaplan DL Hanson DL Cohn, et al. 2003 When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL Clin Infect Dis 37 7 951 958 13130408 10.1086/377606 (Pubitemid 37267212)
34. Palella F, Armon C, Buchacz K, et al. CD4 at HAART initiation predicts long-term CD4 responses and mortality from AIDS and non-AIDS causes in the HIV Outpatient Study (HOPS). In: Proceedings of the 17th Annual Canadian Conference on HIV/AIDS Research, Saskatoon, Canada, May 2010. San Francisco, CA: CROI; 2010. Abstract 983.
35. Antiretroviral Therapy Cohort Collaboration 2010 Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies Clin Infect Dis 50 10 1387 1396 10.1086/652283
36. HIV-CAUSAL Collaboration 2010 The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals AIDS 24 1 123 137 10.1097/QAD.0b013e3283324283